Differences in low-density lipoprotein receptor (LDLR) expression due to mevalonate acid pathway inhibition suggest different cholesterol uptake regulation between primary and metastatic cancer cells (45). This evidence concerns the gene LDLR and metastatic malignant neoplasm.